COBRA REDUCE - Cobra PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

Daniel Weilenmann, Irene Schneider

Hypothesis: In patients undergoing coronary intervention who are receiving oral anticoagulation, Cobra PzF stents with 14 days of DAPT after stenting provide superior outcomes versus Xience/Promus or Resolute drug-eluting stents with 6 months of DAPT after stenting

Randomization: Treatment allocation to Cobra PzF stents with 14 days of DAPT after stenting versus Xience/Promus or Resolute drug-eluting stents with 6 months of DAPT after stenting in 1:1 ratio

Primary Endpoint: Safety: BARC class ≥2 bleeding after hospital discharge (or beyond 14 days whichever is earlier) at 6 months post-randomization

Clinical follow-up: at 14 days, 1, 6 and 12 months

type of project clinical studies
status ongoing - recruiting phase
start of project 2016
end of project 2016
study design Prospective, randomized, active-controlled, open-label assignment, assessor-blinded trial at up to 40 Global sites

responsible person Dr. med. Daniel Weilenmann